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 Fourteen patients with primary bronchogenic carcinoma, in-
cluding 6 stage IIIA patients and 7 IIIB disease patients, under-
went a pulmonary resection following cisplatin-based chemo-
therapy concurrent with 40 Gy of irradiation. The operations 
included 10 lobectomies, a bilobectomy, 2 pneumonectomies 
and a sleeve lobectomy. Dissection of the branches of the 
pulmonary artery was difficult, and an angioplastic proce-
dure was employed in 2 patients. The average operating time 
was 306 minutes, and average blood loss was 338g. All pa-
tients were managed routinely, without any special measures. 
No major postoperative complication occurred, and patients 
were discharged from 11 to 35 days following surgery. Opera-
tive mortality rate was 0%. The median survival time was 
36 months, and the 2-year survival rate was 68%. 
 There is usually a tremendous amount of fibrosis in the 
mediastinum and hilum following induction therapy, and 
therefore, dissection of the adhesion is difficult. However, 
with meticulous dissection, it is possible to perform a suc-
cessful operation without fatal complications.
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Introduction
 The prognosis of primary bronchogenic carcinoma 
remains poor despite recent advances in operation tech-
niques, chemotherapy and radiotherapy. Surgery can 
provide a cure for approximately 70% of the patients 
with stage I lung cancer. However, long-term survival 
rates following resection for stages IIIA and IIIB dis-
ease is unsatisfactory. 
 In an effort to improve upon the poor results given
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by conventional therapy, induction chemotherapy and 
concurrent chemoradiotherapy followed by surgical re-
section have been becoming more promising treatments 
for locally advanced lung cancer. These multimodality 
therapies may contribute to an improved outlook on 
treatment of this deadly illness, however, surgeons must 
be aware of the higher risk of injuring vital organs in 
the thorax compared to conventional pulmonary resec-
tion. 
 This retrospective study summarizes the results of sur-
gical resection following concurrent chemoradiotherapy 
for treatment of lung cancer, and discusses the intra-
and post-operative morbidity and mortality.
Materials and Methods
Patient Population 
 During a period from July 1992 to January 1998, 14 
patients with primary bronchogenic carcinoma con-
secutively underwent thoracotomy after concurrent 
chemoradiotherapy at the Ehime Prefectural Central 
Hospital. The age of the patients at the time of opera-
tion ranged from 48 to 70 years, with the average 
being 59. There were 13 men and one woman in the 
group. Four tumors were on the right, and 10 on the 
left. A histological diagnosis of squamous cell carci-
noma was made in 7 patients, of adenocarcinoma in 4 
and of large cell carcinoma in 2. In one patient, post-
operative pathologic examination revealed no viable 
cells as a result of the induction therapy. Before begin-
ning the induction therapy, 6 patients were judged to 
have had stage IIIA tumors and 7 to have had stage 
IIIB disease (Table 1).
Combined Treatment Modality 
 The chemotherapy regimen consisted of cisplatin (20
Table 1. Data of patients undergoing resection of lung with pri-
mary bronchogenic carcinoma after concurrent chemoradiotherapy
                                 TNM Staging Pathologic TNM 
                Primary Before After 
Case Age Sex Site* Histology** Induction Surgery 
 1 65 M LU Sq T4N2M0 T4N2M0 
 2 49 M LU Ad T4NOMO TINOM0 
 3 59 M RM Sq T2N2MO T2N2M0 
 4 68 F LU La T4N2M0 T0N1M0 
 5 62 M LU Ad T4N2M0 T4NOM0 
 6 66 M LU Sq T4N2M0 TONOM0 
 7 59 M LL Sq T1N1M0 T1NOM0 
 8 48 M RU Ad T3N1M0 T3NOM0 
 9 49 M LL Ad T4N1M0 T3NOM0 
10 63 M LU La T3N2M0 T1N2M0 
11 70 M LU Sq T2N2M0 T3NOM0 
12 48 M LU ? * * * T4NOM0 TxNOM0 
13 53 M RU Sq T2N2M0 T3N1M0 
14 68 M RU Sq T3N2M0 T1NOM0
* LU=left upper lobe; RM=right middle lobe; LL=left lower lobe; 
RU=right upper lobe. 
** Sq=squamous cell carcinoma; Ad=adenocarcinoma; La=large 
cell carcinoma. 
* * * No viable tumor cell was seen .
Mg/M2 on days 1 through 5) and etoposide (40 mg/m2 
on days 1 through 5) infusion, given every third week. In 
3 patients, ifosfamide, vindesine or 5-fluorouracil was 
given as an option to etoposide. Total doses ranged from 
250 to 450 mg for cisplatin, and from 500 to 700 mg for 
etoposide, administered over 5 weeks. A Corticosteroid 
(125 mg of methylprednisolone or 60 mg of prednisolone ) 
was given from the start of chemotherapy with the 
dose tapering off from 15 to 112 days. 
 External radiation therapy to the primary tumor and 
adjacent mediastinum, a dose of 40 Gy (2 courses of 
20 Gy in 10 fractions), was given concurrently with 
chemotherapy over a period of 6 to 7 weeks in 13 pa-
tients. One 48-year-old man underwent 70 Gy of radia-
tion in 56 fractions on days 1 through 38. 
 Two to 34 days, with an average 10 days, following the 
end of irradiation regimen, patients were evaluated for 
clinical response and resectability of their tumors by 
means of fiberoptic bronchoscopy, computed tomography 
(CT) or magnetic resonance imaging (MRI) of the chest. 
 Twenty-four to 76 days, with an average 40 days, 
following the completion of induction treatment, a 
thoracotomy was carried out. The patients underwent 
a lobectomy, bilobectomy or pneumonectomy with hilar 
and mediastinal lymph node dissection. All operations 
were performed under general anesthesia in combina-
tion with epidural anesthesia, and with one-lung venti-
lation by means of a double lumen endotracheal tube. 
In general, dissection of pleural adhesions, mobilization
of the lung, and exposure and dissection of the branches, 
of a pulmonary artery was not easy. Not infrequently, 
it took an hour or more to identify and divide a branch 
of the pulmonary artery. A cord tape tourniquet for 
proximal control of the main pulmonary artery was 
placed for ready use, as a contingency, should the pul-
monary artery become injured. The bronchial stump 
was closed with 3-0 nylon interrupted sutures accord-
ing to Sweet's method. The closed stump was not cov-
ered with pleura or a fat pad. In one case of a right 
upper sleeve lobectomy, the anastomosis was carried 
out with 4-0 monofilament polyglyconate sutures and 
wrapped with a pedicled anterior mediastinal fat pad. 
 Three patients underwent either a combined wedge 
resection of another lobe, a resection of partial pleura 
adjacent to the tumor, or a resection of the adventitia 
of the thoracic aorta. Two patients underwent a left 
upper lobectomy with partial resection of the left main 
pulmonary artery. A right upper sleeve lobectomy was 
carried out on one patient. 
 All patients except one who underwent a left pneu-
monectomy was extubated immediately following com-
pletion of the operation. Postoperative management at 
the intensive care unit (ICU) was discontinued the 
next day in all patients. In the postoperative period, 
corticosteroid was not administered to any patient. All 
patients were managed routinely, and no special meas-
ures were undertaken. Only one patients underwent 
post-operative adjuvant chemotherapy or radiotherapy. 
 Histological typing and TNM staging were classified 
and the effect of the induction therapy (Ef) was graded 
according to the General Rule for Clinical and Patho-
logical Record of Lung Cancer').
Result
 Thirteen of the fourteen patients underwent radical 
resection with histologically negative resection margins. 
One patient who underwent a right upper sleeve lobectomy 
had a microscopically positive margin on the proximal 
end of the bronchial sleeve and was treated with post-
operative radiotherapy (30 Gy in 10 fractions) combined 
with chemotherapy (10 mg of cisplatin for 10 days). 
The operating time ranged from 210 to 440 minutes, 
with an average of 306 minutes. The amount of bleeding 
during the operations ranged from 115 to 668 g, with 
an average of 338 g, and 3 patients received transfu-
sion of 1 to 3 units of packed red blood cells. 
 Trouble with performing a resection of the lung were 
encountered in 12 of the 14 cases, and included diffi-
culty in dissecting dense pleural adhesion in 5, difficulty 
in dissecting the pulmonary artery in 9, an undissectable
interlobar lymph node in 1 and perforation of the bron-
chus in 1 patient (Table 2). 
 Pleural adhesion was awkward, and combined resec-
tion of the parietal pleura was carried out in 3 cases. 
A part of the adventitia of the descending aorta was 
resected in one patient.
Table 2. Intraoperative Difficulties
               Situation No. of Cases 
Difficulty in dissecting adherent pleura 5 
        (Combined resection of parietal pleura) (3) 
Difficulty in dissecting pulmonary artery 9 
        (Pulmonary arterioplasty) (2) 
Undissectable interlobar lymph node 1 
Perforation of proximal bronchus 1
 In 2 of the 9 patients, perivascular fibrosis caused 
difficulty in dividing the branches of the pulmonary 
artery, so techniques of arterioplasty were employed. 
A portion of the side wall of the left pulmonary artery 
was excised and the defect in the artery was oversewn 
using 5-0 polypropylene suture. In the remaining 7 
cases, meticulous dissection of the vascular sheath re-
sulted in the successful dividing of the branches of the 
pulmonary artery. 
 An enlarged lymph node suggesting metastasis was 
fixed onto the side wall of the left pulmonary artery in a 
70-year-old patient, who underwent a pneumonectomy. 
In one patient perforation of the intermediate trunk of 
the right bronchus occurred while dissecting the bron-
chus with adhesion of the interlobar lymph node, but the 
site of the injury was distal to the ultimate line of trans-
ection of the bronchus, so that a successful bilobectomy 
was carried out without a bronchoplastic procedure. 
 Post-surgical pathological examination revealed that 
the effects of induction chemoradiotherapy on the tumors 
were classified as Ef.c (no viable cancer cell) in 4 pa-
tients, Ef.2 (viable cancer cells seen in less than one-
third of the tumor) in 6 patients, and Ef.1 (viable can-
cer cells seen in one-third or more of the tumor) in 4 
patients. 
 Post-operative course was uneventful in 10 of the 14 
patients. There was no operative death, and the hospi-
tal mortality rate was 0%. Three patients had an al-
veolar air leak requiring chest tube drainage for 8 
days or longer. Major complications such as atelectasis, 
pneumonia, respiratory failure, bronchopleural fistula, 
hemothorax and empyema did not occur in any pa-
tient. Hospitalization after the surgery ranged from 11 
to 35 days, with an average of 20 days (Table 3).
Table 3. Post-operative Course
                   Event No. of Patients 
Duration of chest tube drainage 
           3- 5 days 7 
           9-11 days 3
          21-22 days 2
Hospital stay following Surgery 
         11-14 days 4 
         15-21 days 6
         22-35 days 4
Post-operative complications 
          Prolonged air leak 3 
          Pleural effusion 1
 Estimates of survival for the 14 patients, with follow-
up of 5 months to 6 years, showed a median survival 
time of 36 months, and the 2-year survival rate for 
these patients was 68% (Fig. 1). Six patients died of 
cancer 5 to 36 months after the surgery, and there were 
documented disease recurrences in 5 patients, includ-
ing brain metastasis in 2, pulmonary metastasis in 1, 
relapse in the bronchial stump in 1 and carcinomatous 
pleuropericarditis in 1 patient. Two patients who sur-
vived for 37 and 45 months died of perforation of a 
gastric ulcer and infarction of the brain stem, respec-
tively (Table 4).
Fig. 1 Overall probability of survival (death from any cause) 
of 14 patients undergoing pulmonary resection following in-
duction chemoradiotherapy for primary bronchogenic carci-
noma. Zero time on abscissa represents the date of pulmo-
nary resection.
Discussion
 The prognosis of primary lung cancer is unsatisfac-
tory, although surgery may provide a long-term cure 
for selected patients. Long-term chance of survival fol-
lowing the resection of stage III lung cancer is disap-
pointing, and the treatment of advanced disease remains
Table 4. Response and Outcome of Pulmonary Resection 
Following Induction Chemoradiotherapy
                                     Effect of 
                                      Induction
Patient Age Surgery Therapy Follow-up 
   1 65 Lobectomy Ef. 2 5 mo., died 
   2 49 Lobectomy Ef. 2 37 mo., died 
   3 59 Bilobectomy Ef. 1 16 mo., died 
   4 68 Lobectomy Ef. 2 36 mo., died 
   5 62 Lobectomy Ef. C 9 mo., died 
   6 66 Lobectomy Ef. C 31 mo., died 
   7 59 Lobectomy Ef. C 45 mo., died 
   8 48 Lobectomy Ef. 2 7 mo., died 
   9 49 Pneumonectomy Ef. 2 29 mo., alive 
  10 63 Lobectomy Ef. 2 27 mo., alive 
  11 70 Pneumonectomy Ef. 1 26 mo., alive 
  12 48 Lobectomy Ef. C 17 mo., alive 
  13 53 Sleeve lobectomy Ef. 1 10 mo., alive 
  14 68 Lobectomy Ef. 1 5 mo., alive
controversial2 3 4>. Preoperative chemoradiotherapy in pa-
tients with lung cancer is a theoretically attractive con-
cept, in which the tumor size can be reduced, facilitating 
a complete resection and treatment of micrometastases, 
but these theoretical advantages have yet to be proven 
to yield clinical benefit or improve chance of survival. 
 Since the advent of cisplatin, the results of chemo-
therapy for advanced lung cancer have been improv-
ing, and employing irradiation in combination with this 
tumorcidal drug may contribute to survival benefits". 
Improved survival rates for patients with stage III lung 
cancer treated with combination chemotherapy and irra-
diation preoperatively has been reported 6'''8'9,10,">. However, 
physicians should be aware of the risk of perioperative 
mortality and morbidity in this very aggressive treat-
ment"). Actually, a review of the literature revealed that 
the operative mortality for thoracotomy following in-
duction chemoradiotherapy ranged from 5% to 23%, 
although no case of death on the operating table has 
ever been reported678910) 
. 
 Though the amount of fibrosis in the mediastinum and 
hilum following induction therapy varies, the dissection 
of the adhesion is difficult. Dissection of the branches of 
the pulmonary artery is particularly difficult and time-
consuming in an operation following irradiation, and 
therefore surgeons may be reluctant to carry out a 
pulmonary resection. However, patient and meticulous 
dissection can make it possible to perform a successful 
operation and to avoid catastrophically injuring vessels. 
Bronchoplastic and angioplastic procedures can be car-
ried out even following the chemoradiation therapy"). It 
may be preferred to cover the bronchial stump with a 
pedicled flap in order to minimize the possibility of
disrupting the bronchus which may have a deteriorated 
healing capacity following irradiation 13,'4>. However, in the 
present series, nobronchopleural fistula occurred in the 
13 patients undergoing lobectomies or pneumonectornies 
without covering the bronchial stump. Careful dissec-
tion of the bronchus should be carried out to preserve 
as much of the bronchial blood supply as possible, and 
surgeons must not hesitate to employ a covering tech-
nique of the bronchial stump or anastomosis whenever 
they feel uneasy about leaving the suture uncovered. 
 In the present series, the mean operating time was 
306 minutes, which was significantly longer than the 
average of 239 minutes for the 136 operations without 
pretreatment undertaken during the same period. How-
ever, mean blood loss was 338 g, which did not signifi-
cantly differ from the mean of 253 g for the conven-
tional operations. The mean duration of hospital stay 
after surgery was 20 days, which was not significantly 
different from that without induction therapy in this 
institution. Only the length of operating time and awk-
wardness of dissection in a pulmonary resection fol-
lowing induction therapy differed these operations from 
conventional operations. 
 In the present series, postoperative complications in 
4 patients were nonfatal and healed after 9 to 22 days 
with chest tube drainage. However, major and poten-
tially fatal complications such as bronchopleural fistula, 
atelectasis, pneumonia and acute respiratory distress 
after thoracotomy following induction chemoradiotherapy 
are not infrequently seen in the literature"""""'. The ex-
planation for the patients experiencing no major postop-
erative complications in the present series is unclear. One 
may account for it by the use of a corticosteroid dur-
ing the induction therapy, although this was not adminis-
tered postoperatively. Successful bronchovascular recon-
struction after induction chemotherapy postoperatively 
using low dose steroids has been reported"'. 
 The median survival time in the present series was 
36 months, and the 2-year survival rate was 68%. Five or 
more patients suffered recurrences, including 3 patients 
with distant metastases. A locoregional recurrence oc-
curred in one patient whose tumor had no viable cells 
and whose bronchial margin was negative histologically. 
Of the 4 patients who had no histologically viable cancer 
cells in the resected specimen, 2 died of carcinomatous 
pleuropericarditis and pulmonary metastasis. A review 
of the literature revealed median survival time of 17 to 
36 monthssA 101 and 2-year survival rates of 40%" and 
43%101 following concurrent chemoradiotherapy. The 
Lung Cancer Study Group reported that of the 18 pa-
tients who had disease recurrence after complete resec-
tion, none had recurrence only in the chest, and 12 pa-
tients (67%) had recurrence only in distant sites7>.
 Inconsistent staging is the most difficult problem in 
the study of treatment of lung cancer. It is not easy to 
estimate the clinical stage of the disease definitively in 
spite of the advent of computed tomographic scan and 
mediastinoscopy. The evaluation of the postoperative 
stage following induction therapy is even more unreli-
able because it must be altered by preoperative ther-
apy to various degrees. In the operating field, surgeons 
are also unable to determine whether or not the fibrotic 
tissue contains viable cancer cells. Another problem is 
the delay of eradicating the tumor because of the lengthy 
pretreatment period. It takes 50 days or more to com-
plete the concurrent chemoradiotherapy program and 
put the patient on the operating table, and physicians 
fear the disease advances while consuming the time in 
induction therapy and in waiting for operation. 
 The real benefit of induction chemoradiotherapy fol-
lowed by pulmonary resection has not been universally 
approved, and the prognosis of advanced lung cancer 
still remains unsatisfactory even given this aggressive 
multimodality treatment. Better chemotherapeutic agents 
and optimal combination of chemotherapy with radia-
tion need to be established. However, despite the risks 
of operative mortality and morbidity, this discussion of 
the technical aspects and results of surgery following 
chemoradiotherapy will encourage surgeons who are 
involved in or are considering this approach.
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